Privately-held Circassia Ltd of the UK has raised £60 million to be paid over two years from Imperial Innovations Group Plc and other investors in order to finance the development of its T-cell vaccines to treat a range of allergies.
4SC AG has licensed, on an exclusive basis, its investigational pan-histone deacetylase (HDAC) inhibitor for oncology, resminostat, to Yakult Honsha Co Ltd for development and commercialisation in Japan.
F-Star GmbH, the Austrian antibody engineering firm, has raised €15 million from a syndicate of venture capital firms led by SR-One. Other participants were Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare.
Medivir AB has announced an offer to acquire the Nordic speciality pharmaceutical company, BioPhausia AB, in a cash and share offer that values BioPhausia at about SEK 565 million (€62 million). The offer was announced on 11 April 2011.
Venture-capital backed Heptares Therapeutics Ltd of the UK has received £1.7 million upfront in a collaboration deal with the Takeda Pharmaceutical Company to discover drugs for central nervous system disorders focused on a GPCR target.
Two UK speciality pharmaceutical companies, Sinclair Pharma Plc and IS Pharma Plc, have reached agreement on the terms of an all-share merger that will create a new UK-based speciality pharma business with product distribution throughout Europe.
Privately-held Astex Therapeutics Ltd of the UK has agreed to be acquired by the California-based oncology drug developer SuperGen Inc to create a new publicly-listed entity with a combined clinical pipeline of eight products.
Merck & Co has reached agreement to acquire the US speciality pharmaceutical company, Inspire Pharmaceuticals Inc, for $430 million. The transaction has been unanimously approved by the boards of directors of both companies.
Evolva Holding SA of Switzerland, which specialises in synthetic biology, has announced plans to acquire the US venture-capital backed Abunda Nutrition Inc in an all-share transaction valued at approximately CHF 40.5 million (€31.3 million).
MDxHealth SA, the Belgian molecular diagnostics company, is intending to raise at least €6 million with a private placement of its shares managed jointly by Kempen & Co and Nomura Code Securities.